Home・Akciju saraksts・Viking Therapeutics Inc

Viking Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

32.81 0.71

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

32.47

Max

33.51

Galvenie mērījumi
By Trading Economics
Ienākumi	30M -128M
EPS	-1.1
Darbinieki	65
EBITDA	30M -128M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+182.37% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 21. okt.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-245M 3.8B
Iepriekšējā atvēršanas cena	32.1
Iepriekšējā slēgšanas cena	32.81

Ziņu noskaņojums

By Acuity

50%

175 / 340 Rangs Healthcare

Viking Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 4. aug. 23:02 UTC

Social Media

Viking Therapeutics Inc shares are lower in after-market hours amid routine trading. The stock remains below its 20-day moving average.

2026. g. 3. aug. 23:06 UTC

Viking Therapeutics shares are higher in after-market trading, reflecting positive sentiment from stronger-than-expected manufacturing PMI data indicating sector growth.

2026. g. 31. jūl. 23:51 UTC

Viking Therapeutics Inc is higher in after-market trading, recovering from earlier session lows after four consecutive declines. The stock remains below its 20-day moving average.

2026. g. 30. jūl. 23:56 UTC

News

Viking Therapeutics Inc. shows a modest gain in after-market hours amid a wave of biopharmaceutical mergers, including Vertex's $10 billion acquisition of Crinetics.

2026. g. 29. jūl. 23:21 UTC

Social Media

News

Viking Therapeutics reported a Q2 loss of $1.10 per share, better than expected. The company highlighted progress in its obesity treatment pipeline.

2026. g. 28. jūl. 23:11 UTC

News

Viking Therapeutics shares are lower in after-market hours amid ongoing challenges and a significant decline over the past two years. Analysts maintain a bullish outlook.

2026. g. 27. jūl. 23:56 UTC

Viking Therapeutics Inc shares are lower in after-market hours, reflecting a lack of specific news and remaining below the 20-day moving average.

2026. g. 25. jūl. 00:01 UTC

Viking Therapeutics Inc shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down. No specific news was identified.

2026. g. 24. jūl. 21:01 UTC

Viking Therapeutics Inc. is higher in after-market trading, reversing recent losses despite no specific news driving the price movement.

2026. g. 23. jūl. 23:46 UTC

Event

Viking Therapeutics shares are higher in after-market trading ahead of Q2 earnings, with estimated EPS of -$1.21, up from -$0.58.

2026. g. 22. jūl. 23:36 UTC

Viking Therapeutics Inc. shares showed little change during after-market hours, trading within a narrow range and settling near unchanged levels.

Salīdzinājums

Cenas izmaiņa

Viking Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

182.37% augšup

Prognoze 12 mēnešiem

Vidējais 92.08 USD 182.37%

Augstākais 114 USD

Zemākais 70 USD

Pamatojoties uz 14 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Viking Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

14 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 14 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Viking Therapeutics Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

175 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.